Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
Executive Summary
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
You may also be interested in...
When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'
With two new guidance documents, agency is trying to bring order to the potentially chaotic regulatory process that insulins and other currently approved protein products will face in March 2020; FDA also issues two more Q&A guidance documents on scientific and regulatory considerations for biosimilars.
US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics
With an eye toward interchangeable insulins, FDA commissioner says existing protein products that will be 'deemed to be licensed' as biologics in March 2020 will not gain any additional exclusivity; coupled with the loss of existing unexpired exclusivity, the decision may spur innovator lawsuits against the agency for an unconstitutional 'taking.'
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.